000 01805na a2200229 4500
999 _c3284
_d3284
003 PC3284
005 20180417112254.0
008 130622s2013 xxx||||| |||| 00| 0 eng d
040 _cH12O
041 _aeng
100 _aCiruelos Gil, Eva María
_91082
_eOncología Médica
100 _aCortés-Funes Castro, Hernán
_91181
_eOncología Médica
100 _aGhanem Cañete, Ismael
_91793
_eOncología Médica
100 _aManso Sánchez, Luis
_9432
_eOncología Médica
245 0 0 _aRole of inhibitors of mammalian target of rapamycin in the treatment of luminal breast cancer.
_h[artículo]
260 _bAnti-Cancer Drugs,
_c2013
300 _a24(8):769-80.
500 _aFormato Vancouver: Ciruelos E, Cortés-Funes H, Ghanem I, Manso L, Arteaga C. Role of inhibitors of mammalian target of rapamycin in the treatment of luminal breast cancer. Anticancer Drugs. 2013 Sep;24(8):769-80.
501 _aPMID: 23838677
504 _aContiene 75 referencias
520 _aApproximately 75% of patients with breast cancer present hormone receptor-positive tumors. This subtype of breast cancer initially shows a high overall response rate to hormonal treatments. However, resistance eventually develops, resulting in tumor progression. The PI3K/Akt/mTOR pathway regulates several cellular functions in cancer such as cell growth, survival, and proliferation. In addition, a high activation level of the PI3K/Akt/mTOR pathway is related to resistance to conventional chemotherapy and hormone therapy. The mTOR inhibitor everolimus, in combination with hormonal treatments, has led to excellent results in progression-free survival in patients with metastatic breast cancer resistant to hormone therapies. Therefore, everolimus has entered the National Comprehensive Cancer Network (NCCN) guidelines 2012 and its combination with exemestane was approved recently by the US Food and Drug Administration and the European Medicines Agency. This is the first time that a drug will have been approved for the restoration of hormone sensitivity in breast cancer.
710 _9303
_aServicio de Oncología Médica
856 _uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/3/pc3284.pdf
_ySolicitar documento
942 _n0
_2ddc
_cART